Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

10 febbraio 2021 Senza categoria
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento